The Effect of Engineered Mannitol-Lactose Mixture on Dry Powder Inhaler Performance

To co-crystallise mannitol and lactose with a view to obtaining crystals with more favourable morphological features than either lactose or mannitol alone, suitable for use as carriers in formulations for dry powder inhalers (DPIs) using simultaneous engineering of lactose-mannitol mixtures. Mannitol and lactose individually and the two sugars with three different ratios were crystallised/co-crystallised using anti-solvent precipitation technique. Obtained crystals were sieved to separate 63-90 mu m size fractions and then characterised by size, shape, density and in vitro aerosolisation performance. Solid state of crystallized samples was studied using FT-IR, XRPD and DSC. At unequal ratios of mannitol to lactose, the elongated shape dominated in the crystallisation process. However, lactose exerted an opposite effect to that of mannitol by reducing elongation ratio and increasing the crystals' width and thickness. Crystallised beta-lactose showed different anomers compared to commercial lactose (alpha-lactose monohydrate). Crystallised alpha-mannitol showed different polymorphic form compared to commercial mannitol (beta-mannitol). Crystallised mannitol:lactose showed up to 5 transitions corresponding to alpha-mannitol, alpha-lactose monohydrate, beta-lactose, 5 alpha-/3 beta-lactose and 4 alpha-/1 beta-lactose. In vitro deposition assessments showed that crystallised carriers produced more efficient delivery of salbutamol sulphate compared to formulations containing commercial grade carriers. The simultaneous crystallization of lactose-mannitol can be used as a new approach to improve the performance of DPI formulations.